| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Activation of Src family of kinases (SFK) is associated with chronic myeloid leukemia (CML) disease progression and resistance to imatinib (IM) therapy. Activation of SFK can be either Bcr-Abl-dependent or Bcr-Abl-independent in IM-resistant CML patients and clinical importance of this phenomenon is not completely understood. Second generation of tyrosine kinase inhibitors (TKIs) such as dasatinib, targeting both Bcr-Abl kinase as well as SFK, could represent a logical alternative for treatment of patients with acquired IM resistance due to SFK activation. Recent studies raised question whether overexpression of SFK could lead to an acquired resistance to dasatinib. Sensitivity of individual patients? leukemia cells to TKIs can be carried out by assessment of inhibition of phosphorylation of Crkl and SFK after incubation of patient?s leukocytes with the drug in vitro. We used 10 ?M IM or 250 nM dasatinib in vitro and detection with western blot analysis with anti-Crkl 32H4 monoclonal antibody (Cell
- Activation of Src family of kinases (SFK) is associated with chronic myeloid leukemia (CML) disease progression and resistance to imatinib (IM) therapy. Activation of SFK can be either Bcr-Abl-dependent or Bcr-Abl-independent in IM-resistant CML patients and clinical importance of this phenomenon is not completely understood. Second generation of tyrosine kinase inhibitors (TKIs) such as dasatinib, targeting both Bcr-Abl kinase as well as SFK, could represent a logical alternative for treatment of patients with acquired IM resistance due to SFK activation. Recent studies raised question whether overexpression of SFK could lead to an acquired resistance to dasatinib. Sensitivity of individual patients? leukemia cells to TKIs can be carried out by assessment of inhibition of phosphorylation of Crkl and SFK after incubation of patient?s leukocytes with the drug in vitro. We used 10 ?M IM or 250 nM dasatinib in vitro and detection with western blot analysis with anti-Crkl 32H4 monoclonal antibody (Cell (en)
- Aktivace Src kináz (SFK) je úzce spjata s progresí nemoci chronická myeloidní leukémie (CML) a její rezistence na léčbu imatinibem (IM). Bylo prokázáno, že aktivace SFK může být u CML pacientů rezistentních na léčbu IM buď závislá nebo nezávislá na Bcr-Abl, tento fenomén však nebyl zatím blíže vysvětlen. Léčba inhibitory tyrozinkinázových kináz (TKI) druhé generace jako je dasatinib, které cíleně inhibují jak Bcr-Abl kinázu tak i SFK, pak může reprezentovat vhodnou alternativu k léčbě pacientů rezistentních na léčbu IM, u kterých byla zjištěna aktivace SFK. Poslední studie se tak zabývají otázkou, zda může zvýšené exprese SFK vést rovněž k získání rezistence na dasatinib. (cs)
|
| Title
| - Bcr-Abl-independent activation of Src kinases associated with development of dasatinib resistance in a CML patient
- Bcr-Abl-independent activation of Src kinases associated with development of dasatinib resistance in a CML patient (en)
- Rezistence na dasatinib u CML pacientů spojená s aktivací Src kináz nezávisle na Bcr-Abl (cs)
|
| skos:prefLabel
| - Bcr-Abl-independent activation of Src kinases associated with development of dasatinib resistance in a CML patient
- Bcr-Abl-independent activation of Src kinases associated with development of dasatinib resistance in a CML patient (en)
- Rezistence na dasatinib u CML pacientů spojená s aktivací Src kináz nezávisle na Bcr-Abl (cs)
|
| skos:notation
| - RIV/61989592:15110/08:00007430!RIV09-MSM-15110___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/08:00007430
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Bcr-Abl; Src kinase; dasatinib resistance; chronic myeloid leukemia (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Faber, Edgar
- Indrák, Karel
- Jarošová, Marie
- Balcárková, Jana
- Holzerová, Milena
- Divoký, Vladimír
- Mojzíková, Renáta
- Urbánková, Helena
- Veselovská, Jitka
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)